| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise | - | - | 1,576,366 | 1,421,471 |
| Cost of goods and services sold | - | - | 287,005 | 329,110 |
| Gross profit | - | - | 1,289,361 | 1,092,361 |
| Depreciation, depletion and amortization | - | - | 739,449 | 717,838 |
| Research and development expense | - | - | 588,355 | 368,798 |
| Selling, general and administrative | 990,737 | 1,800,778 | 2,301,305 | 2,286,630 |
| Total operating expenses | 990,737 | 1,800,778 | 3,629,109 | 3,373,266 |
| Loss from continuing operations | -990,737 | -1,800,778 | -2,339,748 | -2,280,905 |
| Derivative, gain (loss) on derivative, net | - | - | 202,000 | 1,614,000 |
| Change in fair value of warrant liability | -1,000 | 329,343 | - | - |
| Interest income | 67,014 | 88,849 | 75,817 | 119,391 |
| Amount of the cost of promissory notes accounted for as interest expense for debt | - | - | 158,730 | 114,512 |
| Total other income, net | 68,014 | -240,494 | 119,087 | 1,618,879 |
| Loss before income taxes | -922,723 | -2,041,272 | -2,220,661 | -662,026 |
| Loss from continuing operations, net of tax | -922,723 | -2,041,272 | - | - |
| Gain (loss) from discontinued operations | - | 500,816 | - | - |
| Gain from assignment of subsidiaries and vivus settlement | - | 6,973,302 | - | - |
| Net income (loss) | -922,723 | 5,432,846 | -2,220,661 | -662,026 |
| Preferred stock dividend and cash premiums | 231,210 | - | 1,051,695 | 216,798 |
| Preferred stock, accretion of redemption discount | - | - | 1,974,359 | 1,856,095 |
| Net income (loss) available to common stockholders, basic | - | - | -5,246,715 | -2,734,919 |
| Net loss from continuing operations attributable to common stockholders | -1,153,933 | - | - | - |
| Earnings per share, basic | -0.03 | -1.29 | -0.53 | -0.37 |
| Earnings per share, diluted | -0.03 | -1.29 | -0.53 | -0.37 |
| Weighted average number of shares outstanding, basic | 42,284,502 | 25,922,503 | 9,829,793 | 7,388,107 |
| Weighted average number of shares outstanding, diluted | 42,284,502 | 25,922,503 | 9,829,793 | 7,388,107 |
Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc. (PTPI)